BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17636424)

  • 1. Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Pichette R; Plante M; Durocher F;
    Fam Cancer; 2007; 6(4):483-90. PubMed ID: 17636424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations.
    Oros KK; Ghadirian P; Greenwood CM; Perret C; Shen Z; Paredes Y; Arcand SL; Mes-Masson AM; Narod SA; Foulkes WD; Provencher D; Tonin PN
    Int J Cancer; 2004 Nov; 112(3):411-9. PubMed ID: 15382066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
    Arcand SL; Maugard CM; Ghadirian P; Robidoux A; Perret C; Zhang P; Fafard E; Mes-Masson AM; Foulkes WD; Provencher D; Narod SA; Tonin PN
    Breast Cancer Res Treat; 2008 Apr; 108(3):399-408. PubMed ID: 17541742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.
    Tonin PN; Maugard CM; Perret C; Mes-Masson AM; Provencher DM
    Fam Cancer; 2007; 6(4):491-7. PubMed ID: 17636423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
    Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
    Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
    Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
    Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
    [No Abstract]   [Full Text] [Related]  

  • 11. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
    J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
    Cavallone L; Arcand SL; Maugard CM; Nolet S; Gaboury LA; Mes-Masson AM; Ghadirian P; Provencher D; Tonin PN
    Fam Cancer; 2010 Dec; 9(4):507-17. PubMed ID: 20694749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
    Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG
    Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
    Simard J; Dumont M; Moisan AM; Gaborieau V; Malouin H; Durocher F; Chiquette J; Plante M; Avard D; Bessette P; Brousseau C; Dorval M; Godard B; Houde L; ; Joly Y; Lajoie MA; Leblanc G; Lépine J; Lespérance B; Vézina H; Parboosingh J; Pichette R; Provencher L; Rhéaume J; Sinnett D; Samson C; Simard JC; Tranchant M; Voyer P; Easton D; Tavtigian SV; Knoppers BM; Laframboise R; Bridge P; Goldgar D
    J Med Genet; 2007 Feb; 44(2):107-21. PubMed ID: 16905680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.